Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and Ilomastat block Bacillus anthracis lethal factor activity in viable cells

Infection and Immunity

Volumn 73, Issue 11, 2005, Pages 7548-7557

  Kocer, Salih S ^a   Walker, Stephen G ^a   Zerler, Brad ^c   Golub, Lorne M ^a   Simon, Sanford R ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c State University of NY at Stony Brook ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 9 AMINO 6 NOR 6 DEOXY 4 DE(DIMETHYLAMINO)TETRACYCLINE; BACTERIAL TOXIN; CMT 300; CMT 308; ILOMASTAT; LETHAL TOXIN; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTHRAX; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GENE; BACTERIAL VIRULENCE; CELL STRAIN; CELL STRAIN MONOMAC 6; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LETHAL GENE; MONOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; TOXIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INDOLES; MAP KINASE KINASE 2; MAP KINASE KINASE 6; METALLOPROTEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TETRACYCLINES; TRYPTOPHAN;

EID: 27744459397     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.11.7548-7557.2005     Document Type: Article

References (49)

1. Barletta, J. P., G. Angella, K. C. Balch, H. G. Dimova, G. A. Stern, M. T. Moser, G. B. van Setten, and G. S. Schultz. 1996. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Investig. Ophthalmol. Vis. Sci. 37:20-28.
2. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. T. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229.
3. Bradley, K. A., J. Mogridge, G. Jonah, A. Rainey, S. Batty, and J. A. Young. 2003. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J. Biol. Chem. 278:49342-49347.
4. Brossier, F., and M. Mock. 2001. Toxins of Bacillus anthracis. Toxicon 39:1747-1755.
5. Carney, D. E., C. J. Lutz, A. L. Picone, L. A. Gatto, G. Bailey, M. Fillinger, and G. F. Neiman. 1999. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation 100:400-406.
6. Cianfrocca, M., T. P. Cooley, J. Y. Lee, M. A. Rudek, D. T. Scadden, L. Ratner, J. M. Pluda, W. D. Figg, S. E. Krown, and B. J. Dezube. 2002. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol. 20:153-159.
7. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
8. Cotter, C. S., M. A. Avidano, S. P. Stringer, and G. S. Schultz. 1996. Inhibition of proteases in Pseudomonas otitis media in chinchillas. Otolaryngol. Head Neck Surg. 115:342-351.
9. Cummings, R. T., S. P. Salowe, B. R. Cunningham, J. Wiltsie, Y. W. Park, L. M. Sonatore, D. Wisniewski, C. M. Douglas, J. D. Hermes, and E. M. Scolnick. 2002. A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc. Natl. Acad. Sci. USA 99:6603-6606.
10. Dell'Aica, L, M. Dona, F. Tonello, A. Piris, M. Mock, C. Montecucco, and S. Garbisa. 2004. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. 5:418-422.
11. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
12. Galardy, R. E. 1993. Galardin. Drugs Future 18:1109-1111.
13. Galardy, R. E., M. E. Cassabonne, C. Giese, J. H. Gilbert, F. Lapierre, H. Lopez, M. E. Schaefer, R. Stack, M. Sullivan, B. Summers, R. Tressler, D. Tyrrell, J. Wee, S. D. Allen, J. J. Castellot, J. P. Barletta, G. S. Shultz, L. A. Fernandez, S. Fisher, T. Cui, H. G. Foellmer, D. Grobelny, and W. M. Holleran. 1994. Low molecular weight inhibitors in corneal ulceration. Ann. N. Y. Acad. Sci. 732:315-323.
14. Golub, L. M., T. F. McNamara, G. D'Angelo, R. A. Greenwald, and N. S. Ramamurthy. 1987. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J. Dent. Res. 66:1310-1314.
15. Golub, L. M., T. F. McNamara, N. S. Ramamurthy, H. M. Lee, S. R. Simon, B. L. Lokeshwar, M. G. Selzer, and N. L. Block. 17 November 1998. Method of inhibiting cancer growth. U.S. patent 5,837,696.
16. Golub, L. M., N. S. Ramamurthy, T. F. McNamara, R. A. Greenwald, and B. R. Rifkin. 1991. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 2:297-321.
17. Grobelny, D., L. Poncz, and R. E. Galardy. 1992. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31:7152-7154.
18. Gu, Y., H. M. Lee, E. J. Roemer, L. Musacchia, L. M. Golub, and S. R. Simon. 2001. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr. Med. Chem. 8:261-270.
19. Hanna, P. 1999. Lethal toxin actions and their consequences. J. Appl. Microbiol. 87:285-287.
20. Hao, J. L., T. Nagano, M. Nakamura, N. Kumagai, H. Mishima, and T. Nishida. 1999. Effect of galardin on collagen degradation by Pseudomonas aeruginosa. Exp. Eye Res. 69:595-601.
21. Ho, D. T., A. J. Bardwell, M. Abdollahi, and L. Bardwell. 2003. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J. Biol. Chem. 278:32662-32672.
22. Kirby, J. E. 2004. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 72:430-439.
23. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
24. Lacy, D. B., D. J. Wigelsworth, H. M. Scobie, J. A. Young, and R. J. Collier. 2004. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 101:6367-6372.
25. Levy, G. A., and T. S. Edgington. 1980. Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J. Exp. Med. 151:1232-1244.
26. Mallya, S. K., J. E. Hall, H. M. Lee, E. J. Roemer, S. R. Simon, and L. M. Golub. 1994. Interaction of matrix metalloproteinases with serine proteinase inhibitors. New potential roles for matrix metalloproteinase inhibitors. Ann. N. Y. Acad. Sci. 732:303-314.
27. McCann, U. G., L. A. Gatto, B. Searles, D. E. Carney, C. J. Lutz, A. L. Picone, H. J. Schiller, and G. F. Neiman, 1999. Matrix metalloproteinase inhibitor: differential effects on pulmonary neutrophil and monocyte sequestration following cardiopulmonary bypass. J. Extra-Corpor. Technol. 31:67-75.
28. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
29. Montecucco, C., F. Tonello, and G. Zanotti. 2004. Stop the killer: how to inhibit the anthrax lethal factor metalloprotease. Trends Biochem. Sci. 29:282-285.
30. Nieman, G., A. Picone, C. Lutz, D. Carney, L. Gatto, L. M. Golub, S. R. Simon, and N. S. Ramamurthy. 2 November 1999. Method of preventing acute lung injury. U.S. patent 5,977,091.
31. Panchal, R. G., A. R. Hermone, T. L. Nguyen, T. Y. Wong, R. Schwarzenbacher, J. Schmidt, D. Lane, C. McGrath, B. E. Turk, J. Burnett, M. J. Aman, S. Little, E. A. Sausville, D. W. Zaharevitz, L. C. Cantley, R. C. Liddington, R. Gussio, S. Bavari. 2004. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 11:67-72.
32. Pannifer, A. D., T. Y. Wong, R. Schwartzenbacher, M. Renatus, C. Petosa, J. Bienkowska, B. D. Lacy, R. J. Collier, S. Park, S. H. Leppla, P. Hanna, and R. C. Liddington. 2001. Crystal structure of the anthrax lethal factor. Nature 414:229-233.
33. Pantanowitz, L., and B. J. Dezube. 2004. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr. Opin. Oncol. 16:443-449.
34. Pellizzari, R., C. Guidi-Rontani, G. Vitale, M. Mock, and C. Montecucco. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN-γ-induced release of NO and TNFα. FEBS Lett. 462:199-204.
35. Popov, S. G., T. G. Popova, E. Grene, F. Klotz, J. Cardwell, C. Bradburne, Y. Jama, M. Maland, J. Wells, A. Nalca, T. Voss, C. Bailey, K. Alibek. 2004. Systemic cytokine response in murine anthrax. Cell Microbiol. 6:225-233.
36. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, T. Popova, A. Wu, D. Alibek, C. Bailey, and K. Alibek. 2002. Effect of Bacillus enthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett. 527:211-215.
37. Rifkin, B. R., A. T. Vernillo, and L. M. Golub. 1993. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J. Periodontol. 64:819-827.
38. Rudek, M. A., W. D. Figg, V. Dyer, W. Dahut, M. L. Turner, S. M. Steinberg, D. J. Liewehr, D. R. Kohler, J. M. Pluda, E. Reed. 2001. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19:584-592.
39. Segel, I. H. 1993. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. John Wiley & Sons, Inc., New York, N.Y.
40. Sellman, B. R., S. Nassi, and R. J. Collier. 2001. Point mutations in anthrax protective antigen that block translocation. J. Biol. Chem. 276:8371-8376.
41. Simon, S. R., E. J. Roemer, L. M. Golub, and N. E. Ramamurthy. 30 June 1998. Serine proteinase inhibitory activity by hydrophobic tetracycline. U.S. patent 5,773,430.
42. Swain, P. K., N. K. Sarkar, M. Sharma, S. Goel, R. P. Singh, and Y. Singh. 1997. Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes. Indian J. Biochem. Biophys. 34:186-191.
43. Syed, S., C. Takimoto, M. Hidalgo, J. Rizzo, J. G. Kuhn, L. A. Hammond, G. Schwartz, A. Tolcher, A. Patnaik, S. G. Eckhardt, and E. K. Rowinsky. 2004. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res. 10:6512-6521.
44. Turk, B. E., T. Y. Wong, R. Schwarzenbacher, E. T. Jarrell, S. H. Leppla, R. J. Collier, R. C. Liddington, and L. C. Cantley. 2004. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11:60-66.
45. Vitale, G., L. Bernardi, G. Napolitani, M. Mock, and C. Montecucco. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352:739-745.
46. Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/theronine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711.
47. Wigelsworth, D. J., B. A. Krantz, K. A. Christensen, D. B. Lacy, S. J. Juris, R. J. Collier. 2004. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J. Biol. Chem. 279:23349-23356.
48. Zerler, B., E. Roemer, H. Raabe, A. Sizemore, A. Reeves, and J. Harbell. 2000. Evaluation of the phototoxic potential of chemically modified tetracyclines with the 3T3 neutral red uptake phototoxicity test, p. 545-554. In M. Balls, A.-M. Zeller, and M. Halder, Progress in the reduction, refinement and replacement of animal experimentation. Elsevier, Amsterdam, The Netherlands.
49. Ziegler-Heitbrock, H. W. L., E. Thiel, A. Fütterer, V. Herzog, A. Wirtz, and G. Riethmüller. 1988. Establishment of a human cell line (MonoMac 6) with characteristics of mature monocytes. Int. J. Cancer. 41:456-461.